AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Global Antibiotics Market by Action Mechanism and Drug Class, 2019 to 2026 - RNA and Folic Acid Synthesis Inhibitors are Anticipated to Witness Healthy CAGRs - ResearchAndMarkets.com

February 25, 2019

DUBLIN--(BUSINESS WIRE)--Feb 25, 2019--The “Antibiotics Market Size, Share & Trends Analysis Report By Action Mechanism (Protein, DNA, RNA, Cell Wall Synthesis Inhibitors), By Drug Class (Penicillin, Cephalosporins, Fluoroquinolones), And Segment Forecasts, 2019 - 2026” report has been added to ResearchAndMarkets.com’s offering.

The global antibiotics market size is expected to reach USD 62.06 billion by 2025 expanding at a CAGR of 4%.

Rising prevalence of infectious diseases, especially in developing regions like Asia Pacific and Middle East, is anticipated to contribute to the market growth. More than 15% of the deaths in children below the age of five years, are estimated to be due to pneumonia and according to the statistics provided by the WHO about 9.2 million deaths were recorded in 2015.

Similar to tuberculosis, the disease is highly prevalent in the South Asian and Sub-Saharan regions. Currently, the required antibiotic treatment is available only to one-third of the infected population, thereby increasing the disease burden.

Government reforms specific to antibiotics, such as the Generating Antibiotics Incentives Now (GAIN) Act in U.S., are projected to help boost the market growth over the forecast period. This is further expected to facilitate development of advanced drugs.

According to an article published by the Pew Charitable Trusts, nearly 30% of the outpatient oral antibiotics prescriptions are unnecessary and majority of these are prescribed for disease conditions, such as non-bacterial infections and acute respiratory conditions, against which antibiotics are not significantly effective. Such indiscriminate use of antibiotics is anticipated to increase the risk of difficult-to-treat antibiotic-resistant infections, thereby increasing the economic burden.

Further key findings from the study suggest:

  • RNA and folic acid synthesis inhibitors are anticipated to witness healthy CAGRs over the forecast period
  • Development of several antiviral drugs, which inhibit transcription and reverse transcription process are anticipated to support this growth
  • Asia Pacific is anticipated to witness the highest CAGR over the forecast period on account of large population base, prevalence of infectious diseases, regulation reforms, and wide usage of generic medicine
  • Latin America, especially Brazil, is also projected to exhibit remunerative growth due to strong growth in pharmaceutical sector
  • Outbreak of certain viruses, such as Ebola, in African region contributed to the region’s growth
  • Some of the key companies in the market are Pfizer, Inc, Janssen Pharmaceuticals, Abbott laboratories, GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly & Company, and Astellas Pharma, Inc.

Topics Covered

Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Information procurement
1.3. Information analysis
1.4. Market formulation & data visualization
1.5. Data validation & publishing

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Antibiotics Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis, by Stage
3.4. User perspective analysis
3.4.1. Consumer Behavior Analysis
3.4.2. Market Influencer Analysis
3.5. List of Key End-users, by region / by product / by country
3.6. Regulatory Framework
3.6.1. Reimbursement framework
3.6.2. Standards & Compliances
3.7. Market Dynamics
3.7.1. Market Driver Analysis
3.7.2. Development of advanced products
3.7.3. Increasing prevalence of` infectious diseases
3.7.4. Rising collaborative development efforts
3.7.5. Market Restraint Analysis
3.7.6. Uncertain regulatory policies
3.7.7. High R & D cost
3.7.8. Development of resistance against antibiotics
3.7.9. Industry Challenges
3.7.10. Increasing resistance to antibiotics
3.8. Antibiotics: Market Analysis Tools

Chapter 4. Antibiotics Market: Segment Analysis, By Action Mechanism, 2015 - 2026 (USD Million)
4.1. Definitions & Scope
4.2. Action mechanism market share analysis, 2018 & 2026
4.3. Segment Dashboard
4.4. Global Antibiotics Market, by Action Mechanism, 2015 to 2026
4.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following

Chapter 5. Antibiotics Market: Segment Analysis, By Drug Class, 2015 - 2026 (USD Million)
5.1. Definitions & Scope
5.2. Action mechanism market share analysis, 2018 & 2026
5.3. Segment Dashboard
5.4. Global Antibiotics Market, by Drug Class, 2015 to 2026
5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following

Chapter 6. Antibiotics Market: Regional Market Analysis, 2015 - 2026 (USD Million)
6.1. Definitions & Scope
6.2. Regional market share analysis, 2018 & 2026
6.3. Regional Market Dashboard
6.4. Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
6.5. Regional Market Share and Leading Players, 2018
6.6. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
6.7. Market Size, & Forecasts, and Trend Analysis, 2018 to 2025:
6.8. North America
6.9. Europe
6.10. Asia Pacific
6.11. Latin America
6.12. Middle East and Africa

Chapter 7. Antibiotics Market - Competitive Analysis
7.1. Recent developments & impact analysis, by key market participants
7.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
7.3. Vendor Landscape
7.4. Public Companies
7.5. Private Companies
7.6. Supplier Ranking
7.7. Key companies profiled

  • Pfizer Inc.
  • Janssen Pharmaceuticals
  • Abbott
  • GlaxoSmithKline PLC
  • Sanofi
  • Novartis AG
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Astellas Pharma Inc.

For more information about this report visit https://www.researchandmarkets.com/research/l8ztbh/global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190225005637/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs,Antibiotics

KEYWORD:

INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 02/25/2019 09:50 AM/DISC: 02/25/2019 09:50 AM

http://www.businesswire.com/news/home/20190225005637/en